CA125/MUC16
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Primary Accession | Q8WXI7 |
---|---|
Species | Human |
Sequence | Gly12660-Met12923 |
Purity | > 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level | ≤ 1 EU/ µg of protein by LAL method |
Biological Activity | Immobilized Human CA125, His & Avi Tag at 5.0 µg/ml (100 µl/Well). Dose response curve for Human MSLN with the EC50 of 3.78 µg/ml determined by ELISA. |
Expression System | Expi293 |
Formulation | Lyophilized from a 0.22 µm filtered solution in PBS, pH 7.4. Normally 5 % trehalose is added as protectant before lyophilization. |
Reconstitution | It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in distilled water up to 100 µg/ml. |
Storage & Stability | Upon receiving, this product remains stable for up to 6 months at -70°C or -20°C. Avoid repeated freeze-thaw cycles. |
Gene ID | 94025 |
---|---|
Other Names | Mucin-16, MUC-16, Ovarian cancer-related tumor marker CA125, CA-125, Ovarian carcinoma antigen CA125, MUC16 (HGNC:15582) |
Target Background | MUC16, also known as the CA125 antigen, is a mucin protein that may be found in type I transmembrane or secreted forms that are used monitor the progress of epithelial ovarian cancer therapy. Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. Binding to MSLN mediates heterotypic cell adhesion. This may contribute to the metastasis of ovarian cancer to the peritoneum by initiating cell attachment to the mesothelial epithelium via binding to MSLN. |
Name | MUC16 (HGNC:15582) |
---|---|
Function | Thought to provide a protective, lubricating barrier against particles and infectious agents at mucosal surfaces. |
Cellular Location | Cell membrane; Single-pass type I membrane protein. Secreted, extracellular space. Note=May be liberated into the extracellular space following the phosphorylation of the intracellular C-terminus which induces the proteolytic cleavage and liberation of the extracellular domain |
Tissue Location | Expressed in corneal and conjunctival epithelia (at protein level). Overexpressed in ovarian carcinomas and ovarian low malignant potential (LMP) tumors as compared to the expression in normal ovarian tissue and ovarian adenomas |

Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.

If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.